ORAGENICS INC
OGEN · XNYSCIK 1174940fmd_01QV26V69CSB7H7JJSK3ABHTQEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | – | – | 0 | 0 | 0 | – | – |
| Cost of revenue | 0 | 0 | – | – | – | – | – | – | – | – |
| Gross profit | 0 | 0 | – | – | – | – | – | – | – | – |
| Research and development | 5 | 4 | 6 | 12 | 22 | 11 | 10 | 15 | 4 | 2 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 9 | 7 | 10 | 16 | 27 | 16 | 15 | 21 | 11 | 9 |
| Operating income | (9) | (7) | (10) | (16) | (27) | (16) | (14) | (21) | (11) | (9) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | (0) | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (1) |
| Income before taxes | (8) | (7) | (10) | (16) | (26) | (16) | (14) | (21) | (11) | (10) |
| Income tax expense | 0 | 0 | 0 | – | – | – | – | – | – | (0) |
| Net income from continuing operations | (8) | (7) | (10) | – | – | – | – | – | – | (10) |
| Net income | (7) | (7) | (10) | (16) | (26) | (16) | (14) | (21) | (11) | (10) |
| Net income to common shareholders | – | (7) | (11) | (16) | – | – | – | – | – | – |